Lineage Cell Therapeutics launches new $64.1M at-the-market equity offering

Lineage Cell Therapeutics, Inc.

Prior $25M ATM program terminated; $14.1M remained unsold.
New ATM allows sale of up to $64,133,000 of common shares via Cantor Fitzgerald.
Shares registered under May 2020 and March 2021 shelf registration statements.
Legal opinion of Cooley LLP filed as Exhibit 5.1; proceeds not specified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.